Adam B. Weinstein
CIK 1515170 · EVP, CAO and Director · last filed 2026-03-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.87M
Companies
4
Total Filings
40
Lifetime Open-Market Net
$18.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NMFCZ | EVP, CAO and Director | 751,756 | $25.50 | $19.17M | $1.41M | 4 | 2026-03-18 |
| NMFC | EVP, CAO and Director | 389,715 | $6.92 | $2.70M | $2.02M | 21 | 2022-09-08 |
| New Mountain Finance Corp (NMFX) Delisted | EVP, CAO and Director | 254,941 | — | — | $1.92M | 7 | 2020-09-04 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 326,801 | $0.01 | $3.9K | $12.84M | 5 | 2017-09-26 |
Recent Filings · Page 3 of 4
40 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-09-26 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-03 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | +25,363 | $0 | EDGAR |
| 2016-11-03 | NMFC | Buy (P) | +3,750 | $49.6K | EDGAR |
| 2016-06-21 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-29 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | +16,767 | $0 | EDGAR |
| 2016-02-10 | NMFC | Buy (P) | +2,600 | $29.7K | EDGAR |
| 2015-09-30 | NMFC | Buy (P) | +7,500 | $103.8K | EDGAR |
| 2015-09-11 | NMFC | Buy (P) | +10,500 | $154.2K | EDGAR |
| 2015-02-23 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Mixed | +1,070,166 | $12.84M | EDGAR |
| 2014-11-12 | NMFC | Buy (P) | +5,000 | $73.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.